Investors Sue Biopharma Co. After Clinical Trial Data Toss
Biopharmaceutical company BioVie and three of its executives are facing an investors' proposed class action after "suspected coordinated improprieties" led the company to toss data for over 80% of the subjects...To view the full article, register now.
Already a subscriber? Click here to view full article